" Industry executives said big changes to the agency would also be bad for business, making it difficult for companies with breakthrough treatments to distinguish their products from those that are shams. If standards at the F. D. A. are rolled back, "then we might as well be advertising in the middle of the night on how terrifically we can cure all your illnesses," said Dr. Leonard S. Schleifer, the chief executive of Regeneron, a pharmaceutical company in Tarrytown, N. Y. "Thatâ€™s not the business that I think most of us want to be in. 